Curriculum Vitae
MATTEO MONAMI

INFORMAZIONI PERSONALI

Nome e Cognome	Matteo Monami
Data di nascita	25 marzo 1974
Luogo di nascita	Firenze
Sesso	Maschile
Nazionalità	Italiana
Codice Fiscale	MNMMTT74C25D612D

Recapiti personali:

Indirizzo	Via Domenico Maria Manni n. 2 – 50135 Firenze
Telefono	055.604375 – 338 4027484
E-mail	matteo.monami@unifi.it

Recapiti lavorativi:

Indirizzo	Unit Piede Diabetico, Ponte Nuovo pad. 28, SODc Diabetologia Azienda Ospedaliero-Universitaria Careggi Via delle Oblate, 4 – 50141 Firenze
Telefono	055.7946563–055.7949332
Fax	055.7949660
E-mail	matteo.monami@unifi.it

POSIZIONE ATTUALE

Direttore Unit “Piede Diabetico”
Dirigente Medico I Livello, Disciplina Diabetologia
Azienda Ospedaliero-Universitaria Careggi, Firenze

ESPERIENZA PROFESSIONALE

Dal 05/2016	Direttore Unit “Piede Diabetico” Azienda Ospedaliero-Universitaria Careggi, Firenze
Dal01/2012	Responsabile Servizio Medicazioni Piede Diabetico Azienda Ospedaliero-Universitaria Careggi, Firenze
Dal 10/2008 ad oggi	Dirigente Medico I livello, disciplina Geriatria, tempo indeterminato Cardiologia e Medicina Geriatrica Azienda Ospedaliero-Universitaria Careggi, Firenze
Dal01/2004 al 09/2008	Assegnista di ricerca Unità di Geriatria Università degli Studi di Firenze
Dal 2005 al 2007	Dottorato di ricerca Unità di Geriatria Università degli Studi di Firenze

TITOLI DI STUDIO

25.05.2007 Dottorato di ricerca
Fisiopatologia clinica dell'invecchiamento
Università degli Studi di Firenze
Tesi: "Prevenzione, prognosi e trattamento delle lesioni ulcerative in pazienti anziani diabetici di tipo 2"
Relatore Prof. Giulio Masotti

23.10.2003 Specializzazione in Geriatria
Università degli Studi di Firenze
Voto: 70/70 cum laude
Tesi: "Risposta emodinamica e distrettuale renale alla dopamina in pazienti anziani con scompenso cardiaco congestizio"
Relatore Prof. Niccolò Marchionni

14.10.1999 Laurea in Medicina e Chirurgia
Università degli Studi di Firenze
Voto: 110/110 cum laude

10.07.1993 Maturità Scientifica
Liceo Scientifico P. Gobetti, Firenze
Voto: 56/60

ATTIVITA' DIDATTICA

2004-2005 Docente a Master di I livello in Infermieristica
Docente
Università degli Studi di Firenze

2014 – oggi Scuola Specializzazione in Geriatria
Docente
Università degli Studi di Firenze

2016 – oggi Scuola Specializzazione in Endocrinologia
Docente
Università degli Studi di Firenze

2015 – oggi Corso di Laurea Infermieristica
Docente
Università degli Studi di Firenze

ATTIVITA' EDITORIALI

Membro di Board Editoriali

Attualmente membro del board editoriale delle seguenti riviste:
Internazionali
- Experimental Diabetes Research (2011-2012)
- International Journal of Endocrinology (dal 2013)

Nazionali
- Il Diabete (dal 2013)
- Componente del Comitato Editoriale SID per il biennio 2014 – 2016.

Attività di revisore

Aging Clinical and Experimental Research, ActaDiabetologica, Advances in Therapy, American Heart Journal, Annals of Internal Medicine, Archives of Medical Research, BMC Endocrine Disorders, Diabetes Care, Diabetes Metabolism Research and Reviews, Diabetes Nutrition and Metabolism, Diabetes ResearchandClinical Practice, Diabetic Medicine, Diabetologia, Drugs Aging,, International Journal of Endocrinology , Journal of Diabetes and its complications, Journal ofEndocrinological Investigation, Journal of Internal Medicine, Journal of Sexual Medicine, Nature Reviews Endocrinology, Nutrition Metabolism and Cardiovascular Disease, PLoS ONE.

SOCIETA' SCIENTIFICHE

Società Italiana di Diabetologia (SID)

- Membro del Comitato Editoriale (2014 ad oggi)
- Membro del Direttivo Sezione Regionale Toscana (2011 ad oggi)
- Socio Ordinario (dal 2003)

Società Italiana dell'Obesità (SIO)

- Socio Ordinario (dal 2005-2010)

Società Italiana Geriatria e Gerontologia (SIGG)

- Socio Ordinario (dal 1999)

Società Italiana di Ipertensione Arteriosa (SIIA)

- Socio Ordinario (2000-2002)

ALTRE INFORMAZIONI

Lingua madre Italiano

Altre lingue Inglese, livello avanzato

Competenze informatiche

Buona padronanza di:

- Microsoft Office
- SPSS
- Comprehensive Meta-Analysis

Competenze comunicative

- Ampia esperienza didattica (vedi sopra)
- Relatore a numerosi Congressi Nazionali e Internazionali

Competenze professionali

Esperienza nel disegno di studi clinici, ed in particolare:

- Trial clinici randomizzati;
- Studi epidemiologici trasversali e longitudinali;
- Meta-analisi di trial e studi osservazionali;
- Creazione e validazione di test psicometrici originali

Ha ampia esperienza nell'esecuzione di trial clinici in GoodClinicalPractice (vedi poi).

Nel corso degli anni, ha svolto attività di ricerca nei settori del diabete e malattie cardiovascolarie in particolare:

- Messa a punto e verifica di programmi educativi per il diabete
- Valutazioni epidemiologiche sulle comorbilità nel diabete mellito
- Valutazione di strategie per lo screening del diabete nella popolazione a rischio
- Valutazione dell'efficacia e tollerabilità dei trattamenti per il diabete, attrraverso trial clinici, studi osservazionali e meta-analisi di trial e di studi epidemiologici.

-Valutazioni epidemiologiche su malattie geriatriche e cardiovascolari

PREMI E RICONOSCIMENTI

Congresso SID-AMD 2005 (Prato)

Premio come migliore comunicazione scientifica, con la relazione dal titolo: MORTALITA' PER TUTTE LE CAUSE IN UNA POPOLAZIONE DI DIABETICI DI TIPO 2 TRATTATI CON ASSOCIAZIONI DI SULFANILUREE–BIGUANIDI.

Congresso SID 2016 (Rimini)

Premio Alcmeone 2016 per il miglior curriculum in ambito diabetologico italiano under 45. Il premio consiste in un assegno di 12.500 €.

PRINCIPAL INVESTIGATOR IN TRIAL SPONSORIZZATI

Studio DULCIS	Studio idi confronto tra laser CO2 e bisturi nella eradicazione delle infezioni delle lesioni ulcerative diabetiche. (Completato Febbraio 2016)
Studio GX29915	RCT multicentrico, internazionale, fase 1b su UTTR1147A somministrato sottocute in pazienti diabetici con ulcere recalcitranti del piede.

PUBBLICAZIONI

Numero pubblicazioni

	Totale
Articoli originali	139
Revisioni/editoriali	17
Totale	156

Impact Factor (base 2014)

	Totale
Articoli originali	
Revisioni/lettere	
Totale	571.594

Indici bibliometrici (14/07/2017)

	Google scholar		Scopus
	Totale	*Dal 2013*	*Totale*
h-index	49	42	43
i10-index	120	99	-
Numero citazioni	8413	6027	5631

"Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali"

ELENCO DELLE PUBBLICAZIONI
LIST OF PUBLICATIONS

RIVISTE INTERNAZIONALI CON COMITATO EDITORIALE
INTERNATIONAL PEER-REVIEWED JOURNALS

Articoli originali*
OriginalArticles

Anno	Pubblicazione (IF inerente all'anno di pubblicazione)	IF. 2014	N. citazioni
2002	1. PetruzziE., Pinzani P., Poggesi M., Monami M., Masotti G. Serum Total AntioxidantCapacity (TAC), Dehydroepiandrosteronesulphate (DHEAS) and Insulin-likeGrowth Factor-1 (IGF-1) in HealthyCentenariansubjects, *J EndocrinolInvest*25: 83-84. IF: 1.525	1.552	3
	2. Petruzzi E., Pinzani P., Orlando C., Poggesi M., Monami M., Pazzagli M., Masotti G. Healthy centenarian subjects as living model of "successful aging": A study on fasting glycemia, C-peptide, dehydroepiandrosteronesulphate (DHEAS) and insulin-like growth factor (IGF-1). *Arch GerontolGeriatrSuppl*8:273-278. IF: 1.289	1.525	1
	3. Petruzzi E., Pinzani P., Poggesi M., Monami M., Masotti G. Age-related changes in serum total antioxidant capacity (TAC), dehydroepiandrosteronesulphate (DHEAS), and insulin-like growth factor-1 (IGF-1): evidence in healthy centenarian subjects. Arch GerontolGeriatrSuppl8:265-71. IF: 1.289	1.525	4
2004	1. Mannucci E, Monami M, Masotti G, Marchionni M. All-cause mortality in patients treated with combinations of sulphonylureas and biguanides. *Diabetes-Metab Res Rev* 20: 44-47, 2004. IF 3.133	2.968	44
	2. Mannucci E, SpilaAlegiani S, Monami M, Sarli E, Avogaro A, and the DAI Study Group. Indexes of abdominal adiposity in patients with type 2 diabetes. *J Endocrinol Invest*27: 535-540, 2004. IF 1.525	1.522	10
	3. Barchielli A., BuiattiE., Balzi D., Santoro G.M., Carrabba N., Fabiani P., Maci M., Margheri M., Mangani I., Monami M., Marchionni N. for the AMI-Florence Working Group. Age-Related Changes in Treatment Strategies for Acute Myocardial Infarction: a Population-Based Study (the AMI-Florence Registry). *JAGS*52:1355-60. IF: 3.539	4.216	19
	4. Ungar A, Pepe G, Monami M, Lambertucci L, Torrini M, Baldasseroni S, Tarantini F, Marchionni N, Masotti G. Isolatedambulatoryhypertensioniscommon in outpatientsreferred to a hypertension centre. *J Human Hyper*18:897-903. IF.2.244.	2.692	24
2005	1. Monami M, Mannucci E, Breschi A, Marchionni N. Seizures as the only clinical manifestation of reactive hypoglycaemia. A case report. *J Endocrinol Invest*28: 940-941, 2005. IF 1.525	1.552	5
	2. Ungar A., Di Serio C., Lambertucci L., Monami M., Masotti G. Calcium Channel Blockers and Nephroprotection. *Aging Clinical and Experimental Research*17:31-39. IF: 1.311	1.138	2
2006	1. Balzi D., Barchielli A., Buiatti E., Franceschini C., Mangani I., Del Bianco L., Monami M., Valente S., Gensini G.F., Marchionni N. Age and comorbidity in acute myocardial infarction: a report from the AMI-Florence Italian Registry, for the AMI-Florence Working Group. *Am J GeriatrCardiol*15:35-41.IF.0.689	0.857	1
	2. Balzi D., Barchielli A., Buratti E., Franceschini C, Lavecchia R, Monami M, Santoro GM, Carrabba N, Margheri M, Olivotto I, Gensini GF, Marchionni N. Effect of comorbidity on coronaryreperfusionstrategy and long-termmortalityafter acute myocardialinfarction. *AmHeart J*, 151:1101-1107. IF.3.649	4.555	10
	3. Mannucci E, Monami M, Mannucci M, Chiasserini V, Nicoletti P, Gabbani L, Giglioli L, Masotti G, Marchionni N. Incidence and prognosticsignificance of hypoglycaemia in older non-diabeticpatients in hospital. *AgingClinExp Res*18: 446-451, 2006. IF 1.068	1.138	9

	4.	Monami M, Lambertucci L, Ungar A, Pieri M, Masotti G, Marchionni N, Mannucci E. Is the third component of metabolic syndrome really predictive of outcome in type 2 diabetic patients? *Diabetes Care*29: 2515-2517, 2006. IF 7.912	8.570	16
	5.	Mannucci E, Lambertucci L, Monami M, Fedeli A, Chiasserini V, Marchionni N, Masotti G, Ungar A. Pulse pressure and mortality in hypertensivetype2diabeticpatients. A cohortstudy. *Diabetes-Metab Res Rev*22: 172-175, 2006. IF 2.551	2.968	22
	6.	Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Masotti G, Marchionni N, Mannucci E. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. *Diabetes-Metab Res Rev*22: 482-487, 2006. IF 2.551	2.968	60
	7.	Monami M, Marchionni N, Masotti G, Mannucci E. Fasting and postprandial glycaemia and their correlation with glycatedhaemoglobin in type 2 diabetes. *J Endocrinol Invest*29: 619-624, 2006. IF 1.469	1.552	7
2007	1.	Monami M, Lambertucci L, Lamanna C, Lotti E, Marsilii A, Masotti G, Marchionni N, Mannucci E. Are comorbidity indices useful in the prediction of all-cause mortality in type 2 diabetic patients? Comparison between Charlson index and disease count. *AgingClinExp Res*19: 492-496, 2007. IF 1.460	1.138	11
	2.	Monami M, Balzi D, Lamanna C, Barchielli A, Masotti G, Buiatti E, Marchionni N, Mannucci E. Are sulphonylureasall the same? A cohort study on cardiovascular and cancer-related mortality. *Diabetes-Metab Res Rev*23: 479-484, 2007. IF 3.087	2.968	75
	3.	Monami M, Balzi D, Lamanna C, Melani C, Cocca C, Lotti E, Fedeli A, Masotti G, Marchionni N, Mannucci E.Prognosticvalue of serumliverenzymes in type 2 diabeticpatients. *Diabetes-Metab Res Rev*23: 625-630, 2007. IF 3.087	2.968	9
	4.	Monami M, Marchionni N, Masotti G, Mannucci E. IDF and ATP-III definitions of metabolic syndrome in the prediction of all-cause mortality in type 2 diabetic patients. *Diabetes ObesMetab*9: 350-353, 2007. IF 3.441	5.181	28
	5.	Monami M, Marchionni N, Masotti G, Mannucci E. Prognostic value of IDF and ATP-III definitions of metabolic syndrome in type 2 diabetic patients: what makes the difference? *J Endocrinol Invest*30: 626-630, 2007. IF 2.021	1.552	6
	6.	Mannucci E, Monami M, Bardini G, Ognibene A, Rotella CM. National Cholesterol Education Program (NCEP) and International Diabetes Federation (IDF) diagnostic criteria for metabolic syndrome in an Italian cohort. Results from the FIBAR Study. *J Endocrinol Invest*30: 925-930, 2007. IF 2.021	1.552	8
	7.	Mannucci E, Monami M, Rotella CM. How many components for the metabolic syndrome? Results of exploratory factor analysis in the FIBAR study. *NutrMetabCardiovasc Dis*17: 119-126, 2007. IF 3.174	3.875	17
2008	1.	Balzi D, Barchielli A, Santoro GM, Carrabba N, Buiatti E, Giglioli C, Valente S, Baldereschi G, Del Bianco L, Monami M, Gensini GF, Marchionni N. Management of acute myocardial infarction in the real world: a summary report from the Ami-florenceitalian registry. Internal and Emergency Medicine, 2008, Jun;3(2):109-115. (I.F. 0.000);	2.410	17
	2.	Monami M, Cresci B, Colombini A, Pala L, Balzi D, Gori F, Chiasserini V, Marchionni N, Rotella CM, Mannucci E. Bone fractures and hypoglycaemic treatment in type 2 diabetic patients: a case-control study. *Diabetes Care*31: 199-2003, 2008. IF 7.349	8.570	68
	3.	Monami M, Lamanna C, Marchionni N, Mannucci E.Rosiglitazone and risk of cancer. A meta-analysis of randomized clinical trials. *Diabetes Care*31: 1455-1460, 2008. IF 7.349	8.570	71
	4.	Mannucci E, Monami M, Cresci B, Pala L, Bardini G, Petracca MG, Decembrini I, Pasqua A, Buiatti E, Rotella CM. National Cholesterol Education Program (NCEP) and International Diabetes Federation (IDF) definitions of metabolic syndrome in the prediction of diabetes. Results from the FIBAR Study. *Diabetes ObesMetab*9: 430-435, 2008. IF 4.259	5.181	16
	5.	Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N. Pioglitazone and cardiovascularrisk. A comprehensive meta-analysis of randomized clinical trials. *Diabetes ObesMetab*9: 1231-1238, 2008. IF 4.259	5.181	77
	6.	Monami M, Lamanna C, Gori F, Bartalucci F, Marchionni N, MannucciE.Skinautofluorescence in type 2 diabetes: beyondbloodglucose. *Diabetes Res ClinPract*79: 57-60, 2008. IF 2.754	2.536	24

	7.	Monami M, Lamanna C, Marchionni N, Mannucci E. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. *Diabetes Res ClinPract*79: 196-203, 2008. IF 1.888	2.536	31
	8.	Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH insulin in type 2 diabetes. A meta-analysis. *Diabetes Res ClinPract*81: 184-189, 2008. IF 1.888	2.536	93
	9.	Monami M, Marchionni N, Mannucci E. Winners and losers at the rosiglitazone gamble. A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone. *Diabetes Res ClinPract*82: 48-56, 2008. IF 1.888	2.536	17
	10.	Monami M, Lamanna C, Pala L, Bardini G, Cresci B, Francesconi P, Balzi D, Marchionni N, Rotella CM, Mannucci E. Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients. A retrospective cohort study. *ExpClinEndocrinol Diabetes*116: 184-189, 2008. IF 1.896	1.555	24
	11.	Monami M, Marchionni N, Masotti G, Mannucci E. Effect of combined secretagogue-biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease. *Int J Cardiol*126: 247-251, 2008. IF 3.121	6.175	7
	12.	Monami M, Longo R, Desideri CM, Masotti G, Marchionni N, Mannucci E. The diabetic person beyond a foot ulcer: prognostic value of depressive symptoms. *J Am Pod Med Ass*98: 130-136, 2008. IF 0.586	0.574	23
	13.	Monami M, Lamanna C, Balzi D, Bartalucci F, Melani C, Masotti G, Marchionni N, Mannucci E. Metabolic syndrome and cardiovascular mortality in older type 2 diabetic patients: a longitudinal study. *J Gerontol A Biol Med Sci*23: 625-630, 2007. IF 4.003	4.984	5
	14.	Monami M, Bardini G, Lamanna C, Pala L, Cresci B, Francesconi P, Buiatti E, Rotella CM, Mannucci E. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze-Bagno a Ripoli (FIBAR) study. *Metabolism*57: 387-392, 2008. IF 2.920	3.611	59
2009	1.	Monami M, Pala L, Bardini G, Francesconi P, Cresci B, Marchionni N, Rotella CM, Mannucci E.Glomerularhyperfiltration and metabolicsyndrome: results from the Firenze-Bagno a Ripoli (FIBAR) Study. *Acta Diabetol*46:191-196, 2009. IF 1.549	3.679	9
	2.	Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: a case-control study. *ActaDiabetol*46: 279-284, 2009. IF 1.549	3.679	107
	3.	Ricca V, Castellini G, Mannucci E, Monami M, Ravaldi C, GoriniAmedei S, Sauro CL, Rotella CM, Faravelli C. Amphetaminederivatives and obesity. *Appetite*52: 405-409, 2009. IF 2.582	2.520	11
	4.	Monami M, Vivarelli M, Desideri C, Colombi C, Marchionni N, Mannucci E.Pulse pressure and prediction of incidentfootulcers in type 2 diabetes. *Diabetes Care*32: 897-899, 2009. IF 6.718	8.570	10
	5.	Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues versus regular human insulin in type 2 diabetes: a meta-analysis. *Diabetes ObesMetab*11: 53-59, 2009. IF 4.126	5.181	35
	6.	Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 1 diabetes. A meta-analysis. *Diabetes ObesMetab*11: 372-378, 2009. IF 4.126	5.181	77
	7.	Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. *Eur J Endocrinol*160: 909-917, 2009. IF 3.539	3.686	94
	8.	Monami M, Lamanna C, Marchionni N, Mannucci E. Continuous subcutaneous insulin injection versus multiple daily insulin injections in type 2 diabetes: a meta-analysis. *ExpClinEndocrinolDiab*117: 220-222, 2009. IF 1.685	1.555	26
	9.	UngarA, Pepe G, Lambertucci L, Fedeli A, Monami M, Mannucci E, Gabbani L, Marchionni N, Masotti M, Marchionni N, Di Bari M. Low diastolic ambulatory blood pressure is associated with greater all-cause mortality in older patients with hypertension. *J Am GeriatrSoc*57: 291-296, 2009. IF 3.656	4.216	35
	10.	Corona G, Mannucci E, Jannini EA, Lotti F, Ricca V, Monami M, Boddi V, Bandini E, Balercia G, Forti G, Maggi M. Hypoprolactinemia: a new clinicalsyndrome in patients with sexualdysfunction. *J SexualMed*6: 1457-1466, 2009. IF 4.884	3.150	64
	11.	Corona G, Mannucci E, Lotti F, Boddi V, Jannini EA, Fisher AD, Monami M, Sforza A, Forti G, Maggi M. Impairment of Couple Relationship in Male	3.150	34

		Patients with Sexual Dysfunction is Associated with Overt Hypogonadism. *J Sexual Med*6: 2591-2600, 2009. IF 4.884		
	12.	Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycaemic control in type 2 diabetes. A meta-analysis of randomized clinical trials. *NutrMetabCardiovasc Dis* 19: 604-6012, 2009. IF 3.517	3.875	113
2010	1.	Pala L, Monami M, Lamanna C, Cresci B, Colombi C, Bardini G, Sposato J, Marchionni N, Rotella CM, Mannucci E. Failure to metformin and insulin secretagoguemonotherapy: an observational cohort study. *ActaDiabetol***47(suppl. 1):** 7-11, 2010. IF 3.175	3.679	3
	2.	Monami M, Lamanna C, Marchionni N, Mannucci E. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. *ActaDiabetol***47(suppl. 1):** 77-81, 2010. IF 3.175	3.679	40
	3.	Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, Lamanna C, Bracali I, Bigiarini M, Barchielli A, Marchionni N, Rotella CM. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. *Diabetes Care***33:** 1997-2003, 2010. IF 7.141	8.570	78
	4.	Mannucci E, Monami M, Di Bari M, Lamanna C, Gensini GF, Marchionni N. Cardiacsafetyprofile of rosiglitazone. A comprehensive meta-analysis of randomized clinical trials. *Int J Cardiol***143:** 135-140, 2010. IF 6.802	6.175	35
	5.	Innocenti F, Agresti C, Baroncini C, Caldi F, Mannucci E, Monami M, Pini R. Prognosticvalue of domutamine stress echocardiography in diabeticpatients. *Int J Cardiovasc Imaging* **26:** 499-507, 2010. IF 2.539	2.322	4
	6.	Mannucci E, Pala L, Monami M, Da Vico L, Bardini G, Dicembrini I, Ciani S, Lamanna C, Marchionni N, Rotella CM. Glucagon-like Peptide-1 response to meals and post-prandial hyperglycemia in type 2 diabetic patients. *J Endocrinol Invest***33:** 147-150, 2010. IF 1.476	1.552	3
	7.	Corona G, Monami M, Boddi V, Cameron-Smith M, Fisher AD, De Vita G, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. *J Sexual Med***7:** 1557-1564, 2010. IF 3.957	3.150	73
	8.	Corona G, Monami M, Boddi V, Cameron-Smith M, Lotti F, de Vita G, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Male sexuality and cardiovascular risk: a color study in patients with erectile dysfunction. *J Sexual Med***7:** 1918-1927, 2010. IF 3.957	3.150	61
	9.	Corona G, Monami M, Boddi V, Balzi D, Melani C, Federico N, Sforza A, Rotella CM, Forti G, Mannucci E, Maggi M. Is obesity a further cardiovascular risk factor in patients with erectile dysfunction? *J Sexual Med***7:** 2538-2546, 2010. IF 3.957	3.150	20
	10.	Boddi V, Corona G, Monami M, Fisher AD, Bandini E, Melani C, Balzi D, Sforza A, Patussi V, Forti G,Mannucci E, Maggi M. PriapusisHappier with Venus than with Bacchus. *J Sexual Med***7:** 2831-2841, 2010. IF 3.957	3.150	15
	11.	Bandini E, Fisher AD, Corona G, Ricca V, Monami M, Boddi V, Balzi D, Melani C, Forti G, Mannucci E, Maggi M. Severe Depressive Symptoms and Cardiovascular Risk in Subjects with Erectile Dysfunction. *J Sexual Med***7:** 3477-3486, 2010. IF 3.957	3.150	16
	12.	Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptidyl-Peptidase 4 inhibibitors in type 2 diabetes: a meta-analisys of randomized clinical trials. *NutrMetabCardiovasc Dis***20:** 224-235, 2010. IF 3.438	3.875	111
2011	1.	Monami M, Dicembrini I, Martelli D, Mannucci E.Safety of dipeptydil-peptidase 4 inhbitors. A meta-analysis of randomized clinical trials. *Curr Med Res Opin***27 Suppl 3:** 57-64, 2011. IF 2.380	3.875	111
	2.	Monami M, Colombi C, Balzi D, Dicembrini I, Giannini S, Melani C, Vitale V, Romano D, Barchielli A, Marchionni N, Rotella CM, Mannucci E.Metformin and canceroccurrence in insulin-treatedtype 2 diabeticpatients. *Diabetes Care***34:** 129-131, 2011. IF 8.087	8.570	55
	3.	Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl Peptidase 4 inhibitors and bone fractures. A meta-analysis of randomized clinical trials. *Diabetes Care***34:** 2474-2476, 2011. IF 8.087	8.570	76
	4.	Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. *Diabetes-Metab Res Rev***27:** 362-372, 2011. IF 3.373	2.968	33
	5.	Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. *Diabetes ObesMetab***13:** 221-228, 2011. IF 3.379	5.181	108

	6.	Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, Forti G, Mannucci E, Maggi M. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. *Eur J Endocrinol***165:** 687-701, 2011. IF 3.423	3.686	133
	7.	Monami M, Cremasco F, Lamanna C, Colombi C, Desideri CM, Iacomelli I, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. *Exp Diabetes Res***2011**: 215764, 2011. IF 1.200	1.893	63
	8.	Corona G, Rastrelli G, Boddi V, Monami M, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Prolactin levels independently predict major cardiovascular events in patients with erectile dysfunction. *Int J Androl***34:** 217-224, 2011. IF 3.591	3.206	25
	9.	Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, Forti G, Mannucci E, Maggi M. Type2diabetesmellitus and testosterone: a meta-analysisstudy. *Int J Androl***34:** 528-540, 2011. IF 3.591	3.206	118
	10.	Commisso L, Monami M, MannucciE.Periodontaldisease and oralhygienehabits in a type 2 diabeticpopulation. *Int J DentHyg***9:** 68-73, 2011. IF 0.871	0.682	3
	11.	Bandini E, Fisher AD, Ricca V, Ristori J, Meriggiola M, Jannini EA, Manieri C, Corona G, Monami M, Fanni E, Galleni A, Forti G,Mannucci E, Maggi M. Childhoodmaltreatment in subjects with male-to-female gender identitydisorder. *Int J Impot Res***23:** 276-285, 2011. IF 1.712	1.369	11
	12.	Monami M, Vivarelli M, Desideri CM, Ippolito G, Marchionni N, Mannucci E. Autologous skin fibroblast and keratinocyte grafts in the treatment of chronic foot ulcers in aging type 2 diabetic patients. *J Am Podiatr Med Assoc***101:** 55-58, 2011. IF 0.567	0.574	4
	13.	Corona G, Monami M, Boddi V, Rastrelli G, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Pulse Pressure Independently Predicts Major Cardiovascular Events in Younger But Not in Older Subjects with Erectile Dysfunction. *J Sexual Med***8:** 247-254, 2011. IF 3.552	3.150	13
	14.	Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M. Testosterone and metabolicsyndrome: a meta-analysisstudy. *J SexualMed***8:** 272-283, 2011. IF 3.552	3.150	148
	15.	Corona G, Monami M, Rastrelli G, Melani C, Balzi D, Sforza A, Forti G,Mannucci E, Maggi M. IsMetabolicSyndrome a UselessCategory in Subjects with High CardiovascularRisk? Results from a Cohort Study in Men with Erectile Dysfunction. *J Sexual Med***8:** 504-511, 2011. IF 3.552	3.150	6
	16.	Corona G, Rastrelli G, Monami M, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Body mass index regulates hypogonadism-associated CV risk: results from a cohort of subjects with erectile dysfunction. *J Sexual Med***8:** 2098-2105, 2011. IF 3.957	3.150	25
	17.	Rastrelli G, Corona G, Monami M, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Poor Response to Alprostadil ICI Test is Associated with Arteriogenic Erectile Dysfunction and Higher Risk of Major Adverse Cardiovascular Events. *J Sexual Med***8:** 3433-3345, 2011. IF 3.552	3.150	14
2012	1.	Mannucci E, Monami M, Lamanna C, AldasteinssonJE.Post-prandial glucose and diabetic complications: systematic review of observational studies. *ActaDiabetol***49:** 307-314, 2012. IF 4.631	3.150	14
	2.	Rotella F, Cresci B, Monami M, Aletti V, Andreoli V, Ambrosio ML, Ricca V, Dicembrini I, Mannucci E. Are psychopathological features relevant predictors of glucose control in patients with type 2 diabetes? A prospective study. *ActaDiabetol***49 Suppl 1:** S179-184, 2012. IF 4.631	3.679	8
	3.	Monami M, Lamanna C, Desideri CM, Mannucci E. DPP4 inhibitors and lipids: systematic review and meta-analysis. *AdvTher***29:** 14-25, 2012. IF 2.125	2.438	93
	4.	Monami M, Vitale V, Ambrosio ML, Bartoli N, Toffanello G, Ragghianti B, Monami F, Marchionni N, Mannucci E. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. *AdvTher***29:** 736-746, 2012. IF 2.125	2.438	27
	5.	Baldasseroni S, Antenore A, Di Serio C, Orso F, Lonetto G, Bartoli N, Foschini A, Marella A, Pratesi A, Scarantino S, Fumagalli S, Monami M, Mannucci E, Marchionni N, Tarantini F. Adiponectin, diabetes and ischemicheartfailure: a challengingrelationship. *CardiovascDiabetol***11:**151, 2012. IF 4.209	3.706	11
	6.	Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E. Effects of Glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. *Exp Diabetes Res***2012:** 672658, 2012. IF 1.893	1.893	32

	7.	Fisher AD, Bandini E, Corona G, Monami M, Cameron Smith M, Melani C, Balzi D, Forti G, Mannucci E, Maggi M. Stable extramarital affairs are breaking the heart. *Int J Androl***35:** 11-17, 2012. IF 3.565	3.206	8
	8.	Innocenti F, Baroncini C, Agresti C, Mannucci E, Monami M, Pini R. Left ventricular cavity obliteration during dobutamine stress echocardiography in diabetic patients. *Int J Cardiovasc Imaging***28:** 1023-1033, 2012. IF 2.684	2.322	1
	9.	Giannini S, Bardini G, Dicembrini I, Monami M, Rotella CM, Mannucci E. Lipid levels in obese and nonobese subjects as predictors of fasting and postload glucose metabolism. *J ClinLipidol***6:** 132-138, 2012. IF 2.741	3.587	3
	10.	Monami M, UngarA, Lamanna C, Bardini G, Pala L, Dicembrini I, Marchi C, Vivarelli M, Zannoni S, Bartoli N, Marchionni N, Rotella CM, Mannucci E.Effects of anti-hypertensive treatment on the incidence of diabetes: a case-control study. *J EndocrinolInvest***35:** 135-138, 2012. IF 1.654	1.552	2
	11.	Pala L, Monami M, Ciani S, Dicembrini I, Pasqua A, Pezzatini A, Francesconi P, Cresci B, Mannucci E, Rotella CM. Adipokines as possible new predictors of cardiovascular disease: a case-control study. *J NutrMetab***2012:** 253428, 2012. IF. 0.000	0.000	7
	12.	Fisher AD, Bandini E, Rastrelli G, Corona G, Monami M, Mannucci E, Maggi M. Sexual and Cardiovascular Correlates of Male Unfaithfulness. *J Sex Med***9:** 1508-1518, 2012. IF 3.513	3.150	5
	13.	Corona G, Rastrelli G, Balercia G, Lotti F, Sforza A, Monami M, Forti G, Mannucci E, Maggi M. Hormonal Association and Sexual Dysfunction in Patients with Impaired Fasting Glucose: A Cross-Sectional and Longitudinal Study. *J Sex Med***9:** 1669-1680, 2012. IF 3.513	3.150	22
	14.	Fisher AD, Rastrelli G, Bandini E, Corona G, Balzi D, Melani C, Monami M, Matta V, Mannucci E, Maggi M. Metabolic and cardiovascular outcomes of fatherhood: results from a cohort of study in subjects with sexual dysfunction. *J Sex Med***9:** 2785-2794, 2012. IF 3.513	3.150	10
2013	1.	Da Vico L, Monami M, Biffi B, Lamanna C, Martelli C, Marchionni N, Mannucci E. Targeting educational therapy for type 2 diabetes: identification of predictors of therapeutic success. *ActaDiabetol***50:** 309-317, 2013. IF 4.631	3.150	10
	2.	Monami M, Mannucci E. Efficacy and safety of degludec insulin: a meta-analysis of randomised trials. *Curr Med Res Opin***29:** 339-342, 2013. IF 2.263	2.372	4
	3.	Monami M, Filippi L, Ungar A, Sgrilli F, Antenore A, Dicembrini I, Bagnoli P, Marchionni N, Rotella CM, Mannucci E. Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials. *Curr Med Res Opin***29:** 369-378, 2013. IF 2.263	2.372	14
	4.	Monami M, Ahrén B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. *Diabetes ObesMetab***15:** 112-120, 2013. IF 5.181	5.180	111
	5.	Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M, Facchiano E, Sforza A, Forti G, Mannucci E, Maggi M. Body weight loss reverts obesity-associated ypogonadotropichypogonadism: a systematic review and meta-analysis. *Eur J Endocrinol*. **168:** 829-843. 2013. IF 3.136	3.686	64
	6.	Baldasseroni S, Mannucci E, Di Serio C, Orso F, Bartoli N, Mossello E, Foschini A, Monami M, Valoti P, Fumagalli S, Colombi C, Pellerito S, Gensini G, Marchionni N, Tarantini F. Resistin level in coronary artery disease and heart failure: the central role of kidney function. *J Cardiovasc Med***14:** 150-157, 2013. IF 2.657	1.407	4
	7.	Fisher AD, Bandini E, Casale H, Ferruccio N, Meriggiola MC, Gualerzi A, Manieri C, Jannini E, Mannucci E, Monami M, Stomaci N, Delle Rose A, Susini T, Ricca V, Maggi M. Sociodemographic and clinicalfeatures of gender identitydisorder: an Italianmulticentricevaluation. *J Sex Med* **10:** 408-419, 2013. IF 3.513	3.150	17
	8.	Corona G, Rastrelli G, Ricca V, Jannini EA, Vignozzi L, Monami M, Sforza A, Forti G, Mannucci E, Maggi M. Risk factors associated with primary and secondary reduced libido in male patients with sexual dysfunction. *J Sex Med***10:** 1074-1089, 2013. IF 3.513	3.150	23
	9.	Corona G, Rastrelli G, Silverii A, Monami M, Sforza A, Forti G, Mannucci E, Maggi M. The identification of prediabetes condition with ARIC algorithm predicts long-term CV events in patients with erectile dysfunction. *J Sex Med***10:**1114-1123, 2013. IF 3.513	3.150	10
	10.	Monami M, Vitale V, Lamanna C, Bartoli N, Martelli D, Zannoni S, Antenore A, Toffanello G, Marchionni N, Mannucci E. HbA1c levels and all-cause mortality in type 2 diabetic patients: epidemiological evidence of the need for	3.875	6

	personalised therapeutic targets. *NutrMetabCardiovasc Dis* **23:** 300-306, 2013. IF 3.978		
	11. Monami M, Adalsteinsson JE, Desideri CM, Ragghianti B, Dicembrini I, Mannucci E. Fasting and post-prandial glucose and diabetic complication. A meta-analysis. *NutrMetabCardiovasc Dis***23:** 591-598, 2013. IF 3.978	3.875	4
	12. Corona G, Rastrelli G, Monami M, Maseroli E, Jannini EA, Balercia G, Sforza A, Forti G, Mannucci E, Maggi M. Frequency of sexual activity and cardiovascular risk in subjects with erectile dysfunction: cross-sectional and longitudinal analyses. Andrology. **1**:864-871. IF 3.513	3.513	7
	13. Rastrelli G, Corona G, Vignozzi L, Maseroli E, Silverii A, Monami M, Mannucci E, Forti G, Maggi M. Serum PSA as a Predictorof Testosterone Deficiency. *J Sex Med***10***:* 2518-2528.. IF 3.513	3.150	22
	14. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. *Diabetes ObesMetab*15: 938-953. IF 5.181	5.181	55
	15. Crawford F, Anandan C, Chappell FM, Murray GD, Price JF, Sheikh A, Simpson CR, Maxwell M, Stansby GP, Young MJ, Abbott CA, Boulton AJ, Boyko EJ, Kastenbauer T, Leese GP, Monami M, Monteiro-Soares M, Rith-Najarian SJ, Veves A, Coates N, Jeffcoate WJ, Leech N, Fahey T, Tierney J.Protocol for a systematic review and individual patient data meta-analysis of prognostic factors of foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS). BMC Med Res Methodol**13**:22. (IF 2.168)	2.168	8
2014	1. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. *Diabetes ObesMetab* **16:**48-56. IF 5.181	5.181	8
	2. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. *Diabetes ObesMetab***16**: 38-47. IF 5.181	5.181	43
	3. Monami M, Dicembrini I, Mannucci E.Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials. *ActaDiabetol;***51***(1):91-101*. IF 4.631.	3.679	22
	4. Mannucci E, Genovese S, Monami M, Navalesi G, Dotta F, Anichini R, Romagnoli F, Gensini G. Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled study-the D.A.N.T.E (Diabetic ulcer Antimicrobial New Topical treatment Evaluation) study. *ActaDiabetol*. **51**(3):435-40. IF. 4.631.	3.679	7
	5. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. *Diabetes ObesMetab*. **16**(5):457-66. IF 5.181.	5.181	21
	6. Ambrosio ML, Monami M, Sati L, Marchionni N, Di Bari M, Mannucci E.GLP-1 receptoragonist-inducedpolyarthritis: a case report. *Acta Diabetol.***51**(4):673-4.	3.679	1
	7. Mannucci E, MonamiM, Dicembrini I, Piselli A, Porta M. Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysis.*J Endocrinol Invest*. **37**(5):477-95.	1.552	1
	8. Innocenti F, Bartalucci F, Boni V, Vicidomini S, Mannucci E, Monami M, Pini R. Coronary artery disease screening in type II diabetic patients: prognostic value of rest and stress echocardiography. *Diabetes MetabSyndr*. **8**(1):18-23.	1.250	0
	9. Monami M, Dicembrini I, Kundisova L, Zannoni S, Nreu B, Mannucci E. A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. *Diabetes ObesMetab*.**16**(9):833-40. 6.	5.181	8
	10. Monami M,Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. *Diabetes Res ClinPract*. **103**(2):269-75	2.536	30
	11. MonamiM,Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. *NutrMetabCardiovasc Dis.* **24**(7):689-97.	3.875	50
	12. Monami M, Dicembrini I, Mannucci E .Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials.Diabetes ObesMetab. 2014 Jan;16(1):48-56.	5.180	37

2015	1. Monami M, Ragghianti B, Zannoni S, Vitale V, Nreu B, Mannucci E. Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapies. ActaDiabetol. 2016 Feb;53(1):35-40.	3.679	50
	2. Luconi M, Nreu B, Samavat J, Lorubbio M, Ognibene A, Monami M, Mannucci E. Is early measurement of glycated albumin and HbA1c useful for the prediction of treatment response in type 2 diabetes? ActaDiabetol. 2015 Sep 18. [Epub ahead of print]	3.679	0
	3. Artuso R, Provenzano A, Mazzinghi B, Giunti L, Palazzo V, Andreucci E, Blasetti A, Chiuri RM, Gianiorio FE, Mandich P, Monami M, Mannucci E, Giglio S. Therapeutic implications of novel mutations of the RFX6 gene associated with early-onset diabetes. Pharmacogenomics J. 2015 Feb;15(1):49-54.	3.338	0
	4. Monami M, Zannoni S, Gaias M, Nreu B, Marchionni N, Mannucci E. Effects of a Short Educational Program for the Prevention of Foot Ulcers in High-Risk Patients: A Randomized Controlled Trial.Int J Endocrinol. 2015;Epub-ahead of print.	1.515	0
2016	1. Vitale V, Monami M, Mannucci E. Prostanoids in patients with peripheral arterial disease: A meta-analysis of placebo-controlled randomized clinical trials.J Diabetes Complications. 2016 Jan-Feb;30(1):161-6.	1.925	0
	2. Monami M, Aleffi S. Hyperglycemia, hypoglycemia and glycemic variability in the elderly: a fatal triad? Monaldi Arch Chest Dis. 2016 Jun 22;84(1-2):726. doi: 10.4081/monaldi.2015.726..	0.000	0
2017	1. Monami M, Dicembrini I, Mannucci E. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetol. 2017 Jan;54(1):37-38. doi: 10.1007/s00592-016-0922-5.	3.340	
	2. Ricci L, Scatena A, Tacconi D, Ventoruzzo G, Liistro F, Bolognese L, Monami M, Mannucci E. All-cause and cardiovascular mortality in a consecutive series of patients with diabetic foot osteomyelitis. Diabetes Res Clin Pract. 2017 Jun 15;131:12-17. doi: 10.1016/j.diabres.2017.06.006.	3.639	
	3. Monami M, Nreu B, Zannoni S, Lualdi C, Mannucci E. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. Diabetes Res Clin Pract. 2017 May 18;130:53-60. doi: 10.1016/j.diabres.2017.04.017.	3.639	
	4. Monami M, Nreu B, Scatena A, Giannini S, Andreozzi F, Sesti G, Mannucci E. Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials. J Endocrinol Invest. 2017 May 31. doi: 10.1007/s40618-017-0698-7.	2.633	
	5. Monami M, Zannoni S, Pala L, Silverii A, Andreozzi F, Sesti G, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials. Int J Cardiol. 2017 Aug 1;240:414-421. doi: 10.1016/j.ijcard.2017.03.163.		
	6. Monami M, Scatena A, Zannoni S, Aleffi S, Mirabella C, Giannoni L, Mannucci E. A randomized, open-label, controlled trial to evaluate the antimicrobial and surgical effect of CO2 laser treatment in diabetic infected foot ulcers: DULCIS (diabetic ulcer, CO2 laser, and infections) study. J Endocrinol Invest. 2017 Apr 4. doi: 10.1007/s40618-017-0666-2.	2.633	0
	7. Monami M, Mirabella C, Scatena A, Nreu B, Zannoni S, Aleffi S, Giannoni L, Mannucci E. CO2 laser for the treatment of diabetic foot ulcers with exposed bone. A consecutive series of type 2 diabetic patients. J Endocrinol Invest. 2017 Mar 4. doi: 10.1007/s40618-017-0642-x.	2.633	1
	8. Monami M, Nreu B, Scatena A, Cresci B, Andreozzi F, Sesti G, Mannucci E. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes Obes Metab. 2017 Feb 28. doi: 10.1111/dom.12926.	6.715	0
	9. Mannucci E, Monami M, Ceriello A, Rotella CM. Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes. Nutr Metab Cardiovasc Dis. 2017 Apr;27(4):375-377. doi: 10.1016/j.numecd.2017.01.003.	3.679	1
	10. Rigato M, Monami M, Fadini GP. Autologous Cell Therapy for Peripheral	13.965	

	Arterial Disease: Systematic Review and Meta-Analysis of Randomized, Nonrandomized, and Noncontrolled Studies. Circ Res. 2017 Apr 14;120(8):1326-1340. doi: 10.1161/CIRCRESAHA.116.309045.		
11.	Mannucci E, Monami M. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials. Adv Ther. 2017 Jan;34(1):1-40. doi: 10.1007/s12325-016-0432-4.	2.709	
12.	Mannucci E, Monami M. Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk? Drug Saf. 2017 Feb;40(2):115-119. doi: 10.1007/s40264-016-0470-5.	3.435	
13.	Monami M, Zannoni S, Nreu B, Mannucci E. Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials. Acta Diabetol. 2017 Apr;54(4):411-413. doi: 10.1007/s00592-016-0928-z	3.340	
14.	Dicembrini I, Nreu B, Scatena A, Andreozzi F, Sesti G, Mannucci E, Monami M. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2017 Jul 27. doi: 10.1007/s00592-017-1031-9.	3.340	
15.	Monami M, Dicembrini I, Nreu B, Andreozzi F, Sesti G, Mannucci E. Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials. Acta Diabetol. 2017; 54:1101-1114.	3.340	
1.	Bonora E, Monami M, Bruno G, Zoppini G, Mannucci E. Attending Diabetes Clinics is associated with a lower all-cause mortality. A meta-analysis of observational studies performed in Italy. Nutr Metab Cardiovasc Dis. 2018; 28:431-435.	3.679	0
2.	Monami M, Liistro F, Scatena A, Nreu B, Mannucci E. Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2018 ; 20:1213-1222.	6.715	0

Revisioni ed editoriali
Reviews and Editorials

Anno	Pubblicazione (IF inerente all'anno di pubblicazione)	IF. 2014	N. citazioni
2009	1. Mannucci E, Monami M. Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing*? Curr Diabetes Rep***9:** 324-327, 2009. IF 2.496	3.080	6
	2. Mannucci E, Monami M. Liraglutide and its effects on HbA1c and weight control: a two-year experience. *ObesMetab***5:** 152-155, 2009. IF 0.400	0.400	0
2011	1. Mossello E, Ballini E, Boncinelli M, Monami M, Lonetto G, Mello AM, Tarantini F, Baldasseroni S, Mannucci E, Marchionni N. Glucagon-like Peptide-1, diabetes, and cognitive decline: possible pathophysiological links and therapeutic opportunities. *Exp Diabetes Res***2011:** 281674, 2011. IF 1.200	1.893	12
	2. Monami M. Glucagon-like peptide-1 and diabetes.Exp Diabetes Res. :901954. IF 1.200	1.893	4
2012	1. Paolisso G, Monami M, Marfella R, Rizzo MR, Mannucci E. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? *AdvTher***29:** 218-233, 2012. IF 2.125	2.438	14
	2. Monami M, Di Pasquale G, Rowzee A, Rotella CM, Mannucci E.Glucagon-like peptide-1 and diabetes 2012. *Exp Diabetes Res***2012:** 768760, 2012. IF 1.893	1.893	1

Lettere (osservazioni originali)
Letters (originalobsevations)

2002	1.	Monami M, Mannucci E, Masotti G. Finger sepsis in two poorly controlled diabetic patients with reuse of lancets. *Diabetes Care***25:** 1103, 2002. IF 5.477	8.570	7
	2.	Monami M, Mannucci E, Masotti G. Use of an oxidised regenerated cellulose and collagen composite for healing of chronic diabetic foot ulcers. *Diabetes Care***25:** 1892-1893, 2002. IF 5.477	8.570	1
2007	1.	Mannucci E, Monami M, Pala L, Cocca C, Cresci B, Bardini G, Masotti G, Marchionni N, Rotella CM. Management of type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Response to Nathan et al. *Diabetes Care***30:** 193-194, 2007. IF 7.851	8.570	4
	2.	Mannucci E, Monami M, Bardini G, Sposato I, Ungar A, Pepe G, Masotti G, Marchionni N, Rotella CM. Metabolicsyndrome and pulse pressure. *DiabetesObesMetab***9:** 600-602, 2007. IF 3.441	5.180	8
	3.	Mannucci E, Monami M, Masotti G, Marchionni N. Is basal insulin always the first choice for the initiation in insulin therapy in type 2 diabetic patients? *ExpClinEndocrinol Diabetes***115:** 339-340, 2007. IF 1.745	1.555	0
	4.	Mannucci E, Monami M, Marchionni N. Rosiglitazone and cardiovascularrisk. *N Engl J Med***357:** 938, 2007. IF 54.42	54.42	17
2011	1.	Monami M, Bigiarini M, Rotella CM, Mannucci E.Inaccuracy in meta-analysis on rosiglitazone and myocardialinfarction. *NutrMetabCardiovascDis***21:** e7-e8, 2011. IF 3.731	3.875	7
2013	1.	Mannucci E, Monami M, Dicembrini I, Rotella C. The impossible return to the Garden of Eden: The ORIGIN trial and the original sin of early insulin treatment of type 2 diabetes. *NutrMetabCardiovasc Dis***23:** e35-e36, 2013. IF 3.731	3.875	7

Partecipazione a gruppi di studio - Articoli originali *

2003	1.	Buiatti E, Barchielli A, Marchionni N, Balzi D, Carrabba N, Valente S, Olivotto I, Landini C, Filice M, Torri M, Regoli G, M Santoro G and the AMI-Florence workinggroup. The Determinants of treatment strategies and survival in acute myocardial infarction: a population-based study in the Florence district, Italy. Results of the acute myocardial infarction Florence registry (AMI-Florence), Eur Heart J. 2003, 24(13):1195-1203. (IF: 7.924)
2004	1.	Carrabba N, Santoro GM, Balzi D, Barchielli A, Marchionni N, Fagiani P, Landini C, Scarti L, Santoro G, Valente S, verdini V, Buratti E and the AMI-Florence Working Group. In-hospital Management and Outcome in Women with Acute Myocardial Infarction. (Data from the AMI-Florence Registry). Gender differences in treatment and outcome. Am J Card. 2004, 94(9):1118-1123. (IF: 3.603)
2006	1.	Barchielli A, Balzi D, Marchionni N, Carrabba N, Margheri M, Santoro GM, Olivotto I, Buiatti E and the AMI-Florence working group. Early discharge after acute myocardial infarction in the current clinical practice. Community data from the AMI-Florence Registry, Italy. Int J Card 2006, 114(1):57-63. (IF: 2.878)
2013	1.	Santoro G, Carrabba N, Barchielli A, Balzi D, Marchionni N, Filice M, Valente S, Granelli M, Berni I, Buiatti E. Use and efficacy of abciximab in an unselected population with acute myocardial infarction treated with primary angioplasty: Data from AMI-Florence registry. Atherosclerosis 2007, 195(1):116-121. (IF: 3.811)

*Non rientrano nel calcolo totale dell'Impact Factor.